Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2007

Abraxis Obtains North American and EU Rights to Biocon’s G-CSF Biosimilar

  • Abraxis BioScience licensed the right to develop a biosimilar version of G-CSF (granulocyte-colony stimulating factor) in North America and the EU from Biocon.

    Therapeutic G-CSF is primarily used for the treatment of neutropenia. Biocon received regulatory approval from the Indian DCGI for the treatment of neutropenia in cancer patients.

    Under the terms of the agreement, Biocon will receive an upfront licensing fee and following approval in the licensed territories, royalties from Abraxis BioScience.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »